Based on the studies, that were conducted and in view of the serious risks that certain patient populations are still exposed to, EMA’s safety committee (PRAC) has recommended that marketing authorisations for hydroxyethyl-starch (HES) solutions for infusion should be suspended across the European Union (EU).
For more information see this link.
